首页> 外国专利> Use of N-(2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6 dichlorophenyl)pyrido(2,3-d)pyrimidin-7-yl)-N'-(1,1-dimethylethyl)-urea for the preparation of medicament to treat acute myeloid leukemia and chronic myelogenous leukemia

Use of N-(2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6 dichlorophenyl)pyrido(2,3-d)pyrimidin-7-yl)-N'-(1,1-dimethylethyl)-urea for the preparation of medicament to treat acute myeloid leukemia and chronic myelogenous leukemia

机译:N-(2-(2,1,3-苯并噻二唑-5-基氨基)-6-(2,6-二氯苯基)吡啶基(2,3-d)嘧啶-7-基)-N'-(1, 1-二甲基乙基)-尿素用于制备治疗急性髓细胞性白血病和慢性粒细胞性白血病的药物

摘要

Use of N-[2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6 dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-urea (I) and its hydrates, salts or solvates, for the preparation of medicament to treat leukemia and myeloids leukemia, is claimed. ACTIVITY : Cytostatic. The anti-tumor activity of (I) was tested in severe combined immunodeficient mice CB-17. The result showed that (I) exhibited tumor mass reduction of 80%. MECHANISM OF ACTION : None given.
机译:N- [2-(2,1,3-苯并噻二唑-5-基氨基)-6-(2,6-二氯苯基)吡啶基[2,3-d]嘧啶-7-基] -N'-(1,要求保护用于制备用于治疗白血病和髓样白血病的药物的1-二甲基乙基)-脲(I)及其水合物,盐或溶剂化物。活动:细胞静息。在严重的联合免疫缺陷小鼠CB-17中测试了(I)的抗肿瘤活性。结果显示(I)显示出80%的肿瘤减少。作用机理:未给出。

著录项

  • 公开/公告号FR2910813A1

    专利类型

  • 公开/公告日2008-07-04

    原文格式PDF

  • 申请/专利权人 SANOFI AVENTIS SOCIETE ANONYME;

    申请/专利号FR20060011492

  • 发明设计人 BOURRIE BERNARD;CASELLAS PIERRE;

    申请日2006-12-28

  • 分类号A61K31/519;A61P35/02;

  • 国家 FR

  • 入库时间 2022-08-21 19:47:06

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号